Medical and pharmaceutical

The medical and pharmaceutical industry is developing rapidly which has been increased by COVID-19 pandemic. This industry plays a key role in Poland constituting an important sector of the economy and having a significant influence on the health and well-being of the societies.

Medical and pharmaceutical industry in Poland

In 2022, the total value of the production of pharmaceutical products amounted to more than PLN 14 billion and was 2.6 times higher than the production of medical devices.

The value of pharmaceuticals produced in Poland maintains on relatively stable level and the added gross value is growing: it indicates increased production efficiency and better production cost management.

Get to know the Polish medical-pharmaceutical industry

The report on the Polish medical-pharmaceutical industry includes the characteristics of the industry, the value of production, as well as the structure of pharmaceutical industries and various statistical data.

Download file

Leading pharmaceutical companies operating on the Polish market of medicines and active substances belonging to the Polish Association of Employers of the Pharmaceutical Industry (PZPPF)

Company	Production structure	More
Adamed Pharma SA (Pieńków, Mazowieckie Province, Poland) A Polish company founded in 1986 Share capital PLN 718.4 million	500 Stock Keeping Unit (SKU) products, prescription medicines (RX) (cardiology, oncology, diabetology, pulmonology, other therapeutic groups), over-the-counter (OTC) medicines: food supplements, dermocosmetics, medical devices (eye drops). Licence sales. EU-GMP (Good Manufacturing Practice) certificate Exports – geographical directions 78 countries (Europe, Middle East, Asia, Africa, Latin America, Oceania) Representative offices abroad /other forms of presence on a foreign market Spain, Russia, Czech Republic, Vietnam, Italy, Kazakhstan, Uzbekistan and Slovakia, Ukraine Adamed Pharma SA
Biofarm Sp. z o.o. (Poznań, Poland). A Polish company founded in 1988	180 SKU products, prescription drugs (RX), over-the-counter (OTC) drugs, food supplements, cosmetics, EU-GMP (Good Manufacturing Practice) certificate Exports – geographical directions Austria, Spain, Malta, Portugal, Switzerland, United Kingdom, Italy, Ukraine, Sweden, Albania, Croatia, Cyprus, Greece, Kosovo, Serbia, Panama, Chile, Ecuador, Colombia, Iraq, China, Vietnam, Kazakhstan, Uzbekistan Representative offices abroad /other forms of presence on a foreign market Abroad: Implementation of activities related to establishing long-term cooperation (distribution, in/out licences). Biofarm Sp. z o.o.
Egis Group (Budapest, Hungary). Subsidiary of the Servier Group. ODDZIAŁ EGIS POLSKA SP. Z O.O.	Prescription (RX) medicines, cardiology, oncology, gynecology, dermatology, gastroenterology, medicines, other therapeutic groups, over-the-counter (OTC) medicines Treatment of hypertension and general cardiovascular diseases Exports – geographical directions Egis products are available in 100 countries through a network of subsidiaries, representative offices and partners Representative offices abroad /other forms of presence on a foreign market Subsidiaries have been established in 17 countries Egis Group
Gedeon Richter Polska Sp. z o.o. Grodzisk Mazowiecki, Mazowieckie Province, Poland The company is owned by the foreign company Gedeon Richter.	Prescription (RX) medicines: cardiology, oncology, diabetology, neurology, psychiatry, infectious diseases, other therapeutic groups, over-the-counter (OTC) medicines, GMP (Good Manufacturing Practice) certificate Exports – geographical directions Gideon Richter is a global, innovative pharmaceutical concern with a presence in over 100 countries Representative offices abroad /other forms of presence on a foreign market The parent company Gedeon Richter cooperates with partners from over 100 countries (including Japan, China, USA). Present in Poland since 1994 Gedeon Richter Polska Sp. z o.o.
Glenmark Pharmaceuticals Sp. z o.o Warsaw, Poland. The company is owned by the foreign entity.	Prescription (RX) medicines: psychiatry, neurology, orthopaedics and dermatology, allergology, pulmonology, over-the-counter (OTC) medicines: food supplements, dermocosmetics. GMP (Good Manufacturing Practice) certificate Exports – geographical directions Glenmark Pharmaceuticals sells products in over 80 countries. Representative offices abroad /other forms of presence on a foreign market The company has offices in 30 countries (in Poland since 2008.) Glenmark Pharmaceuticals Sp. z o.o
Przedsiębiorstwo Farmaceutyczne LEK-AM Sp. z o.o. Zakroczym near Warsaw, Poland. A Polish company Net turnover – PLN 268 million (2021)	80 products. Prescription drugs (RX) Psychiatry, urology, pulmonology, cardiology, dermatology. Over-the-counter (OTC) medicines, food supplements, medical devices, cosmetics. GMP (Good Manufacturing Practice) certificate Exports – geographical directions Most of the production is destined for the domestic market. Some of the products are sold on foreign markets. Representative offices abroad /other forms of presence on a foreign market LEK-AM is making great efforts to expand its export business Przedsiębiorstwo Farmaceutyczne LEK-AM Sp. z o.o.
LEK S.A. Lek (a Sandoz Company) LEK S.A. (Sandoz group, part of the Novartis group) Stryków, Łódź Province, Poland	Lek S.A. Manufacturing Plant. Prescription (RX) medicines: painkillers and anti-inflammatory drugs, drugs used to treat diabetes and vascular hypertension. Over-the-counter (OTC) medicines, cosmetics. GMP (Good Manufacturing Practice) certificate Exports – geographical directions Sandoz sells medicines in 140 countries. The medicines produced in Poland by LEK SA are sold in 60 countries Representative offices abroad /other forms of presence on a foreign market Sandoz has 30 production plants worldwide LEK S.A.
Zakłady Farmaceutyczne POLPHARMA S.A. Starogard Gdański, Poland Share capital: PLN 100 million A Polish company Total turnover: PLN 3,996.3 million	800 Stock Keeping Unit (SKU) products Prescription (RX) medicines: cardiology, neurology, ophthalmology, gastroenterology, gynecology. Inpatient medicines. Over-the-counter (OTC) medicines, cosmetics. Food supplements, cosmetics and medical devices. Producer of APIs for the manufacture of finished dosage forms. GMP (Good Manufacturing Practice) certificate. Exports – geographical directions Products of Polpharma S.A. are exported to 30 countries (Central and Eastern Europe, Central Asia). APIs are available in more than 60 countries. They are exported to the USA, Japan and Korea, among other countries Representative offices abroad /other forms of presence on a foreign market Polphrma S.A. engages in the B2C and B2B sale of products on foreign markets and in collaboration with local distributors. Zakłady Farmaceutyczne POLPHARMA S.A.
Polpharma Biologics S.A. Duchnice, Mazowieckie Province, Poland, a Polish company. In 2013, a research and development centre is established in Gdańsk as part of Polpharma S.A., which becomes an independent company in 2019 – a spin-off from Polpharma	Development of biosimilars with significant market potential (Polpharma Biologics 1). Biosimilars are drugs that are developed on the basis of an already known active ingredient of the original preparation on the market and improve patient access to therapy and reduce its costs (Polpharma Biologics 2). For example, the biosimilar Tyruko produced by Polpharma Biologics was authorised for the treatment of relapsing-remitting multiple sclerosis (RRMS) (Polpharma Biologics 5). GMP (Good Manufacturing Practice) certificate Exports – geographical directions The company has a broad portfolio of biosimilars that can be used in many therapeutic areas. Polpharma Biologics S.A. works with the world’s largest foreign biotechnology companies. Representative offices abroad /other forms of presence on a foreign market In 2016, the company began a collaboration with the Dutch biotechnology company Bioceros. In 2019, contract the commercialisation of biosimilars was concluded with Sandoz and the US company Coherus. In 2021, Polpharma signed contract with Teva for the commercialisation of a biosimilar on the European markets and in Canada Polpharma Biologics S.A.
Tarchomińskie Zakłady Farmaceutyczne Polfa S.A. (Polfa Tarchomin) Head office: Warsaw, Poland	Polfa Tarchomin produces drugs in four therapeutic classes: antibiotics and tuberculosis, human insulins, psychotropic drugs and dermatics. The company manufactures 50 products in over 120 different forms. IT specialises in the production of prescription medicines (RX) for hospitals. Polfa Tarchomin is one of the most important manufacturers of injectable antibiotics, with a 48% share of the hospital market. The company is also an API manufacturer. Polfa Tarchomin manufactures over-the-counter medicines, medical devices, dermocosmetics, food supplements, disinfectants and medical masks and has a GMP (Good Manufacturing Practise) certificate. Exports – geographical directions The company mainly produces medicines for the domestic market, with exports accounting for 17% of production Representative offices abroad /other forms of presence on a foreign market Polfa Tarchomin utilises various models of cooperation in export, including representative offices, retail chains, distributors, agents Tarchomińskie Zakłady Farmaceutyczne Polfa S.A.
Vipharm S.A. Head office: Ożarów Mazowiecki, Mazowieckie Province, Poland A Polish pharmaceutical company founded in 1998.	Medicines manufactured by Vipharm S.A. are used in oncology, palliative care, hematology, diabetology, neurology and psychiatry. GMP (Good Manufacturing Practice) certificate Exports – geographical directions Vipharm S.A. has been present in the Czech Republic, Slovakia, Hungary and Germany since 2008. Representative offices abroad /other forms of presence on a foreign market Vipharm has its branches in the Czech Republic, Slovakia, Hungary and Germany. Vipharm S.A.
Servier Polska Sp. z o.o. Warsaw, Poland A foreign company The Servier Group in Poland comprises the following companies: Servier Polska sp. z o.o. (research and development activities, marketing services), Servier Polska Services sp. z o.o. (distribution activities, accounting, purchasing services) and Anpharm Przedsiębiorstwo Farmaceutyczne S.A., Servier’s fifth largest production facility in the world, based in Warsaw.	Servier Polska Sp. z o.o. conducts research in the field of new medical technologies. The Anpharm Przedsiębiorstwo Farmaceutyczne S.A. production facility manufactures drugs for the treatment of high blood pressure, coronary heart disease, heart failure, type 2 diabetes and depression, as well as cardiological drugs. GMP (Good Manufacturing Practice) certificate. Exports – geographical directions 50% of the medicines produced in Poland are exported to 21 countries, mainly to EU countries, including: France, Lithuania, Latvia, Estonia, Slovakia, Croatia, the Czech Republic, Slovenia, Romania, Italy, Bulgaria, Austria, Hungary, Greece, Spain, Malta and Cyprus, as well as Burma, Serbia, Ireland and the United Kingdom. Representative offices abroad /other forms of presence on a foreign market Servier, which is headquartered in France, is also present in more than 150 countries worldwide (3). The sale of pharmaceuticals in certain regions of the world is carried out by four subsidiaries: EGIS (Central and Eastern Europe), Pharlab (Brazil), Swipha (Nigeria) and Biogaran, the market leader in the generics segment in France. Servier Polska Sp. z o.o.
BIOMED SA Wytwórnia Surowic i Szczepionek Head office: Cracow, Poland.	Instytut Biotechnologii Surowic i Szczepionek (Institute of Biotechnology of Serums and Vaccines) BIOMED S.A. is an expert in the field of vaccines and probiotics. A probiotic contains live microorganisms that have a positive effect on the microflora of the patient’s organism. Vaccines protect the population against infectious diseases. Immunostimulating products are created. IBSS BIOMED S.A. products contain probiotic bacterial strains that are used in the prevention and treatment of many diseases. Medicinal products, food supplements, medical devices, cosmetics are offered. The company has a GMP (Good Manufacturing Practice) certificate. Exports – geographical directions IBSS BIOMED S.A. has been selling its products in dozens of countries in Europe, Asia, Africa and Australia for over 10 years. Representative offices abroad /other forms of presence on a foreign market The company cooperates with foreign partners in the registration, promotion and distribution of products. BIOMED SA
Teva Pharmaceuticals Polska Sp. z o.o. Head office: Warsaw, Poland	Teva’s factories produce prescription drugs, over-the-counter drugs and dietary supplements. Around 500 products are manufactured, including painkillers, anti-inflammatory drugs, anti-infectives used for cardiovascular diseases, diseases of the central nervous system, transplantology, oncology and dermatology. The company has a GMP (Good Manufacturing Practice) certificate. Exports – geographical directions Teva Pharmaceuticals Polska Sp. z o.o. exports medicines to the EU. 65% of the Krakow plant’s production is exported. Teva Pharmaceutical Industries Ltd. supplies medicines and active ingredients to markets in more than 60 countries on various continents (North America, South America, Europe, Asia including China and Japan). Representative offices abroad /other forms of presence on a foreign market Teva Pharmaceutical Industries Ltd. operates a network of research institutes, manufacturing plants and trading companies in 30 European countries. Teva Pharmaceuticals Polska Sp. z o.o.

Pharmaceutical companies operating on the Polish market – members of the Warsaw Stock Exchange

Company	Production structure	More
CELON PHARMA S.A. Head office: Kiełpin/Łomianki, Mazowieckie Province, Poland	An integrated pharmaceutical company. The company’s strength lies in its strong research and development facilities (two fully equipped research laboratories), where innovative drugs are developed for the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Celon Pharma S.A. is a manufacturer of inhaled medicines for asthma. The company focuses on the production and distribution of specialised generics (equivalent products). It has a GMP (Good Manufacturing Practice) certificate. Exports – geographical directions Scandinavian markets (Denmark, Sweden, Norway). Projected increase in exports of medicines to the German and UK markets. Increasing export sales (China, Mexico, Saudi Arabia, South Africa). Representative offices abroad /other forms of presence on a foreign market International partnership in the implementation of clinical trial projects. Outside of Poland, medicines are commercialised through business partners such as Glenmark, Viatris (formerly Mylan) and Genericon. CELON PHARMA S.A.
Synthaverse S. A. Head office: Lublin, Poland (formerly Biomed Lublin Wytwórnia Surowic i Szczepionek). The company has been listed on the primary market of the WSE since 2015.	A Polish pharmaceutical company. It manufactures 60 products in various ranges. Specialised in the production of serums and vaccines, immunotherapy (treatment of bladder cancer). Synthaverse also manufactures medical preparations (prescription and over-the-counter drugs), medical devices and laboratory reagents (used in biochemical and medical laboratories). The company is also the developer of a tuberculosis vaccine that is used to immunise all newborns in the country and is widely used around the world. Exports – geographical directions Synthaverse’s products are supplied to more than 50 countries. Representative offices abroad /other forms of presence on a foreign market The company works with business partners in over 20 countries in Europe, Asia and South America. Synthaverse S. A.
BIOTON S.A. Head office: ul. Starościńska 5, Warsaw, Poland. Contact: BIOTON S.A. Zakłady Podukcyjne Macierzysz, ul. Poznańska 12 Ożarów Mazowiecki	Bioton manufactures and distributes medicines and biotechnology products. The company produces clinically important and state-of-the-art drugs, including recombinant human insulin and its pharmaceutical forms, human growth hormone and various antibiotics. The BIOTON plant in Macierzysz near Warsaw is one of the most modern biotechnology facilities in the world. This is where insulin is produced – both the active ingredient and the finished dosage forms. The company has a GMP (Good Manufacturing Practice) certificate. Exports – geographical directions BIOTON S.A. registers its products in many countries around the world. The company’s insulins are available in over 20 countries in Europe, Latin America, Asia and Africa. Representative offices abroad /other forms of presence on a foreign market Sales outside Poland are made on the basis of co-operation agreements and purchase contracts concluded with foreign and domestic partners. BIOTON S.A.
Mabion S.A. Head office: Konstantynów Łódzki, Poland Mabion S.A. debuted on the primary market of the Warsaw Stock Exchange on 23 April 2013	The company specialises in the production of sterile biotechnology products. Mabion S.A. is a Polish biotechnology company established to commercialise the latest generation of biotechnological drugs based on humanised monoclonal antibodies. This technology enables the production of targeted drugs that act selectively on cancer cells and offer improved efficacy and reduced toxicity of therapy. Mabion Sp. z o.o. was founded by six domestic pharmaceutical companies: Polfarmex S.A., Instytut Biotechnologii Surowic i Szczepionek BIOMED S.A., CelonPharma Sp. z o.o, Genexo Sp. z o.o., Biotech Consulting Sp. z o.o. and Bio-Centrum Sp. z o.o. Exports – geographical directions Mabion Sp. z o.o. cooperates with Novavax, an US biotechnology company. Mabion will conduct stability studies on intermediates and substances produced and used in the manufacturing process of the SARS-CoV-2 rS agent of the Nuvaxovid vaccine. Representative offices abroad /other forms of presence on a foreign market The company expands international cooperation in areas affecting the success of activities of the CDMO (Contract Development and Manufacturing Organization) Mabion S.A.

Companies operating on the Polish market, members of the Warsaw Stock Exchange in the health care sector’s group “medical equipment and supplies”

Company	Production structure	More
Mercator Medical S.A. Cracow, Poland. The company’s manufacturing facility is located in Thailand.	Mercator Medical S.A. manufactures disposable medical devices (gloves), medical dressings and non-woven protective products, e.g. medical clothing and surgical drapes Exports – geographical directions The company is active in more than 60 countries and offers around 120 products: both its own and those of other renowned international brands. Representative offices abroad /other forms of presence on a foreign market Subsidiaries of the company are located in 10 countries: Thailand, Ukraine, Romania, Hungary, Russia, Czech Republic, Italy, Germany, Netherlands, France Mercator Medical S.A.
SDS Optic S.A. Lublin, Poland The company debuted on the NewConnect market on 15 March 2022	SDS Optic S.A. develops medical technologies that combine fibre optic optoelectronics (photonics), molecular biology, immunochemistry and modern medical bioengineering techniques. The company also works in the field of technologies for diagnostic devices and the monitoring of life processes in their natural state and in real time, focusing on cancer, infectious, viral, bacterial and fungal disease. The company has developed inPROBE®, the world’s first fibre-optic microprobe for real-time cancer diagnosis with the first application area of HER2+ breast cancer detection. Exports – geographical directions Commercialization of inPROBE technology on a global scale Representative offices abroad /other forms of presence on a foreign market Participation in the trade fairs MEDICA2021 in Düsseldorf, Life Science Open Space 2021 conferences, European Innovation Council Summit 21. Presentation of the product and technology internationally, establishment of business relationships and outreach to potential end users. SDS Optic S.A.